At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving ...

John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

These activities are further supported by the in-vivo data demonstrating that both the NKG2A and CD3 arms contribute to the ...

See the incredible transformation of FrenchieFries' parents' house into a million-dollar dream home! Featuring a full ...

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical ...

Texas Parks and Wildlife wants your opinion on a new license plate design showing a horned lizard.

MIT and Scripps scientists explore a single-dose vaccine approach by combining two immune-boosting ingredients.

UCSF researchers recently created the world's first shape-shifting synthetic proteins using artificial intelligence (AI). The ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Sr ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...